Investigation of liver autoantibodies in anticentromere antibody positive patients: A preliminary research

Öz

Background: Anticentromere antibody (ACA) is regarded to be a serological marker specific to CREST (calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactylia, and telangiectasia) syndrome. ACA is also found in the sera of patients with autoimmune liver disease. In the present work, anti-soluble liver antigen\liver pancreas antigen (anti-SLA\LP), anti-liver cytosolic antigen 1 (anti-LC1), anti-liver kidney microsomal antigen 1 (anti-LKM1), and anti-mitochondrial antibody M2 (AMA-M2) were evaluated in the patients who had positive anticentromere antibody.

Material and Methods: A total of 39 patients who were positive anticentromere antibody were enrolled in this study undertaken in the Izmir Katip Celebi University, Ataturk Training and Research Hospital, Microbiology laboratory between January and September 2015. Positive anticentromere antibody and liver autoantibodies were analyzed. Anticentromere antibody and liver autoantibodies were studied by indirect immunofluorescence method (IIF) and immunoblotting method (IB), respectively. The patients who had negative anticentromere antibody were used as a control group.

Results: According to the study’s results, positivity was detected in 3 of 39 patients (%7.6) in terms of liver autoantibodies, all of which were AMA-M2. There was no statistically significant difference between ACA and autoimmune liver autoantibodies.

Conclusion: In this study, we reported our preliminary experience to provide evidence for the detection of various autoantibodies as potential diagnostic or prognostic tests. Further studies that contain a broad range of patients may contribute to the field.

Anahtar Kelimeler

• Anticentromere antibody,autoimmune hepatitis,immunofluorescence method

Kaynakça

1. Caramaschi P, Tonolli E, Biasi D, Caimmi C, Pieropan S, Dal Forno I, Scambi C, Adami S. Antinuclear autoantibody profile in systemic sclerosis patients who are negative for anticentromere and anti-topoisomerase I specificities. Joint Bone Spine 2015; 82: 209-210.
2. Sánchez-Montalvá A, Fernández-Luque A, Simeón CP, Fonollosa-Plà V, Marín A, Guillén A, Vilardell M. Anti-SSA/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study. Clin Exp Rheumatol 2014;32: 177-182.
3. Grace M, Varada, Dhanesh E. Digital gangrene associated with anticentromere antibodies. Indian J Dermatol 2014; 59: 195-196.
4. Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 2005; 32: 1488-1494.
5. Marie I, Levesque H, Tranvouez JL, François A, Riachi G, Cailleux N, Courtois H. Autoimmune hepatitis and systemic sclerosis: a new overlap syndrome? Rheumatology (Oxford) 2001; 40: 102-106.
6. Kojima H, Uemura M, Sakurai S, Ann T, Ishii Y, Imazu H, Yoshikawa M, Ichijima K, Fukui H. Clinical features of liver disturbance in rheumatoid diseases: Clinicopathological study with special reference to the cause of liver disturbance. J Gastroenterol 2002; 37: 617-625.
7. Manns MP, Lohse AW, Vergani D. Autoimmune hepatitis-Update 2015. J Hepatol 2015; 62: 100-111.
8. Bogdanos DP, Mieli-Vergani G, Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 2009; 29: 241–253.

9. Himoto T, Murota M, Yoneyama H, Deguchi A, Kurokochi K, Senda S, Haba R, Watanabe S, Nishioka M, Masaki T. Clinical characteristics of patients with autoimmune hepatitis seropositive for anticentromere antibody. Hepatol Res 2010; 40: 786-792.
10. Lodh M, Pradhan D, Parida A. Autoimmune hepatitis with anti-centromere antibodies. Case Reports Immunol 2013; 2013: 742080.
11. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008; 14: 3374-3387.
12. You BC, Jeong SW, Jang JY, Goo SM, Kim SG, Kim YS, Jeon CH, Jeen YM. Liver cirrhosis due to autoimmune hepatitis combined with systemic sclerosis. Korean J Gastroenterol 2012; 59: 48-52.
13. Onozuka Y, Shibata M, Yonezawa H, Terauti K, Miyachi K, Ueno Y. Clinical significance of anti-centromere antibody and anti-CENP-B antibody in sera of patients with primary biliary cirrhosis. Rinsho Byori 1996; 44: 877-882.
14. Chan HL, Lee YS, Hong HS, Kuo TT. Anticentromere antibodies (ACA): clinical distribution and disease specificity. Clin Exp Dermatol 1994; 19: 298-302.
15. Salliot C, Gottenberg JE, Bengoufa D, Desmoulins F, Miceli-Richard C, Mariette X. Anticentromere antibodies identify patients with Sjögren's syndrome and autoimmune overlap syndrome. J Rheumatol 2007; 34: 2253-2258.
16. Csepregi A, Szodoray P, Zeher M. Do autoantibodies predict autoimmune liver disease in primary Sjögren's syndrome? Data of 180 patients upon a 5 year follow-up. Scand J Immunol 2002; 56: 623-629.